Tech Company Inital Public Offerings
Reata Pharmaceuticals IPO
Reata Pharmaceuticals, based in Irving, had an IPO event on 5/26/2016.
Transaction Overview
Company Name
Announced On
5/26/2016
Transaction Type
IPO
Amount
$60,500,000
Proceeds Purpose
We intend to use the net proceeds from this offering as follows: approximately $30 million to advance the development of bardoxolone methyl through a Phase 3 clinical trial for the treatment of CTD-PAH; approximately $6 million to advance the development of bardoxolone methyl through Phase 2 clinical programs for the treatment of four etiologies of PH-ILD; approximately $15 million to advance the development of omaveloxolone, including completion of the MOXIe and MOTOR Phase 2 clinical trials; and the remainder for working capital and other general purposes, including our preclinical studies and clinical trials, although we have not allocated specific dollar amounts to such purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
2801 Gateway Dr. 150
Irving, TX 75063
USA
Irving, TX 75063
USA
Phone
Website
Email Address
Overview
Reata Pharmaceuticals, Inc. (NASDAQ: RETA) is a biopharmaceutical company focused on developing novel treatments for cancer, inflammation, and neurodegenerative diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Warren Huff
Chief Financial Officer
Jason Wilson
Chief Medical Officer
Colin Meyer
VP - Bus. Development
Dawn Bir
VP - Bus. Development
Keith Ward
VP - Finance
Elaine Castellanos
VP - General Counsel
Michael Wortley
VP - Marketing
David Chapman
VP - R & D
Christian Wigley
VP - Regulatory Affairs
Joel Proksch
Browse more venture capital transactions:
Prev: 5/26/2016: Daktari Diagnostics venture capital transaction
Next: 5/26/2016: Votiro venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs